Pharmaceutical Industry Articles & Reports

A 2026 guide to AccessGUDID API v3, record-key identity, version-aware schemas, daily and full-release ingestion, terminology enrichment, and reconciliation controls for medical device data.

2026 control matrix for Claude Managed Agents in GxP workflows: auto and always_ask outcomes, non-overridable denials, MCP versus custom tools, audit evidence, validation tests, and pilot metrics.

A 2026 antibody R&D comparison of Benchling Biologics, Genedata Biologics, and IDBS Polar across format modeling, registration, assay and sample lineage, interfaces, GxP, and a buyer-run proof of concept.

A 2026 protocol for validating CDISC Dataset-JSON 1.1 against XPT: canonical datasets, schema and metadata checks, round trips, nulls and precision, signed evidence, and FDA submission status.

A 2026 comparison of entity registration and physical sample logistics across Mosaic, RegMol, Dotmatics and Certara, with modality rules, integration boundaries and a migration reconciliation template.

A 2026 data atlas of FDA BIMO inspections by fiscal year, inspected party and classification, with source-deck revisions, denominator rules, observation families and control priorities.

A 2026 governance framework for AI assistants in pharma and biotech R&D, covering WHO BRIET guidance, project approvals, monitoring, evidence retention, metrics, and tabletop testing.

A 2026 implementation guide to CDISC USDM 4.0, its API and Handbook 1, with a TA/TE/TV/TI/TS mapping, amendment controls, validation gates, and a bounded pilot worksheet.

A 2026 implementation guide to ClinicalTrials.gov API v2 covering REST and bulk access, page-token ingestion, schema drift, record history, provenance, and reproducible trial-intelligence pipelines.

A 2026 pharma control-architecture guide to Claude in Chrome transcripts, including six-year retention, 600-request API sizing, DLP, SIEM, eDiscovery, and Part 11 boundaries.

A 2026 Define-XML 2.1 implementation guide covering field-level metadata controls, FDA version selection, value-level tests, link integrity, and reviewer navigation.

Compare Quartzy, Labguru, SciNote and LabArchives in 2026 across 25 RFP criteria, five workflow tests, inventory traceability, procurement, ELN links, compliance evidence and export paths.

A 2026 operational guide to FDA study data standards version selection, including catalog dates, SDTM, SEND, ADaM, Define-XML, and rejection preflight controls.

A 2026 implementation guide to EMA shortage prevention plans, covering the two-day retrieval rule, field-level data ownership, risk thresholds, ESMP boundaries and mid-2027 readiness.

A 2026 guide to EMA NAM pilot eligibility, four regulatory applicability areas, pathway selection, Module 2.4 package design, and evidence-readiness scoring.

A 2026 evidence matrix for FDA digitally derived measures, covering endpoint roles, verification, validation, missingness, change control, and a stride-length example.

A 2026 analyst guide to FDA's GenAI medical device discussion paper, with a two-axis risk matrix, competency evidence plan, lifecycle monitoring controls, and 30/60/90-day readiness actions.

A 2026 evidence-based blueprint for the Novo Nordisk Anthropic collaboration, covering disclosed scope, Claude Science governance, stage gates, and a 90-day R&D scorecard.

A 2026 operating guide to FDA eSTAR 7.0 version control, sequential PDF editing, technical-screening QA, CDRH Portal limits, and controlled 510(k) and De Novo responses.

A 2026 deployment and validation guide to Anthropic's 36 biomolecular optimization kits, Exact/Fast/Big modes, H100 benchmarks, and pharma pilot gates.

A 2026 analysis of Claude Enterprise pharma data security, including EFS customer-owned storage, retention and HIPAA boundaries, rollout questions, and a cloud-cost worksheet.

A 2026 implementation guide to ICH M11 CeSHarP covering the final template, technical specification, FDA and EMA dates, system crosswalks, amendments, terminology, and a 20-control readiness score.

A 2026 GxP integration cost benchmark framework covering scope classes, validation evidence, timeline fields, TCO formulas, rework and maintenance measures.

Compare HALO, Visiopharm, and Aiforia for preclinical pathology in 2026, including modalities, custom AI, GLP evidence, deployment, integration, cost questions, and a buyer-run bake-off.